The prodrug oxcarbazepine is an antiepileptic agent structurally resembling carbamazepine but differing in its metabolism. Oxcarbazepine inhibits voltage-dependent sodium channels resulting in an interruption of the epileptical discharge [1] . Oxcarbazepine is extensively metabolized by the liver into the active metabolite 10-monohydroxy-carbazepine (MHD) via cytosolic keto-reductase enzymes. MHD is predominantly deactivated through uridine diphosphateglucuronyltransferase (UGT) into glucuronide conjugates and by oxidation into 10,11-dihydroxy-derivative (DHD, only about 4 %) [2] . Urinary excretion comprises of 49 % MHD glucuronides, 27 % MHD, 9 % oxcarbazepine glucuronides, and <1 % unchanged oxcarbazepine [3] . Oxcarbazepine and MHD inhibit cytochrome P 450 (CYP) 2C19 and induce CYP3A4 and CYP3A5 but lack the ability for autoinduction [4] .
To the Editors:
The prodrug oxcarbazepine is an antiepileptic agent structurally resembling carbamazepine but differing in its metabolism. Oxcarbazepine inhibits voltage-dependent sodium channels resulting in an interruption of the epileptical discharge [1] . Oxcarbazepine is extensively metabolized by the liver into the active metabolite 10-monohydroxy-carbazepine (MHD) via cytosolic keto-reductase enzymes. MHD is predominantly deactivated through uridine diphosphateglucuronyltransferase (UGT) into glucuronide conjugates and by oxidation into 10,11-dihydroxy-derivative (DHD, only about 4 %) [2] . Urinary excretion comprises of 49 % MHD glucuronides, 27 % MHD, 9 % oxcarbazepine glucuronides, and <1 % unchanged oxcarbazepine [3] . Oxcarbazepine and MHD inhibit cytochrome P 450 (CYP) 2C19 and induce CYP3A4 and CYP3A5 but lack the ability for autoinduction [4] .
Strong enzyme inducers, such as carbamazepine, phenytoin, or phenobarbital are known to decrease the serum concentration of MHD by 13-40 % [5] [6] [7] [8] . Rifampicin is another potent inducer of CYP enzymes, P-glycoprotein (P-gp), and UGT [9] . However, potential effects of rifampicin on the pharmacokinetics of oxcarbazepine are unknown.
Here, we present a 33-year-old female (BMI 27.5 kg/m 2 , active smoker) on long-term oxcarbazepine treatment at a daily dose of 1,200 mg for epilepsy. Due to therapy-resistant acne vulgaris, rifampicin 600 mg daily and clindamycin 300 mg b.i.d. were initiated. Therapeutic drug monitoring (TDM) of oxcarbazepine and MHD trough concentrations was conducted before, during, and after the course of antibiotic therapy on days 0, 3, 7, 14, 21, 35, 59, 83, and 92 ( Fig. 1) . Coadministration with rifampicin resulted in a significant decrease of MHD serum concentrations by 49 % on day 7, while o x c a r b a z e p i n e c o n c e n t r a t i o n s r e m a i n e d s t a b l e . Oxcarbazepine dosing was adapted to maintain MHD concentrations within the therapeutic range. A 75 % increase of the initial oxcarbazepine dose (final daily dose 2,100 mg) was required to achieve similar MHD target concentrations during rifampicin treatment compared to baseline. After discontinuation of rifampicin, MHD serum concentrations increased despite an initial oxcarbazepine dose reduction. Finally, the oxcarbazepine dose could be reduced to baseline dosage of 1,200 mg resulting in similar MHD concentrations before the rifampicin treatment. The patient did not experience any epileptic seizure and adverse reaction during and after the period of coadministered rifampicin. This is the first report on coadministration of rifampicin and oxcarbazepine. To our knowledge, the exact mechanism of the interaction between oxcarbazepine and enzyme inducers is not known. MHD concentration-tooxcarbazepine dose ratio on day 7 ( Fig. 1 ) was similar to previous results with other inducers [10] . Similar effects might play a role with rifampicin as the magnitude of the effect was comparable. However, a more pronounced decrease of MHD concentrations cannot be ruled out due to oxcarbazepine dose adjustments guided by TDM. Moreover, the effect on MHD concentrations might be dependent on the dose of rifampicin. Recently, MHD exposure was shown to be increased by 10 % during coadministration of the P-gp inhibitor verapamil [11] . Since rifampicin is known to induce P-gp, UGT, and CYP, a combination of different pharmacokinetic alterations, such as decreased bioavailability of oxcarbazepine and enhanced degradation, might result in diminished MHD concentrations.
Serum levels between 10 and 35 mg/L have been suggested for the prevention of epileptic seizures [12] . Although the clinical significance of this drug-drug interaction is not exactly known, decreased MHD concentrations may result in a potential reduction of oxcarbazepine efficacy leading to seizures. If oxcarbazepine and rifampicin are administered concurrently, clinical response to oxcarbazepine may need to be monitored. Dose adaptations of oxcarbazepine might be necessary after initiation and discontinuation of the potent enzyme-inducer rifampicin. Further studies are required to clarify the exact pharmacokinetic mechanism and magnitude of the drugdrug interactions as well as the role of TDM of the active metabolite MHD during this combination therapy.
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